Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health
NCT07915687, Phase 2, Not yet recruiting, Universiti Teknologi Mara
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health | ClinicalTrials.gov |
| NCT number | NCT07915687 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 190 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Universiti Teknologi Mara | ClinicalTrials.gov |
| Conditions | Dyslipidemia | ClinicalTrials.gov |
| Interventions | Synbiotic (LAB12 and SWEOAT® Bran), Oat-based Placebo | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) | Baseline and Week 12 | Evaluated as the absolute change in LDL-C concentrations from baseline. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Gut Microbiota Profile | Baseline and Week 12 | Analyzed via 16S rRNA sequencing to assess changes in microbial diversity and relative abundance of taxa | ClinicalTrials.gov |
| Secondary | Change from Baseline in Total Cholesterol (TC) | Baseline and Week 12 | Evaluated as the absolute change in serum Total Cholesterol | ClinicalTrials.gov |
| Secondary | Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) | Baseline and Week 12 | Evaluated as the absolute change in serum HDL-C | ClinicalTrials.gov |
| Secondary | Change from Baseline in Triglycerides (TG) | Baseline and Week 12 | Evaluated as the absolute change in serum Triglycerides | ClinicalTrials.gov |
| Secondary | Change from Baseline in Apolipoprotein B (ApoB) | Baseline and Week 12 | Evaluated as the absolute change in serum ApoB levels | ClinicalTrials.gov |
| Secondary | Change from Baseline in Hemoglobin A1c (HbA1c) | Baseline and Week 12 | Evaluated as the absolute change in HbA1c percentage | ClinicalTrials.gov |
| Secondary | Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) | Baseline and Week 12 | Evaluated as the absolute change in plasma hsCRP levels | ClinicalTrials.gov |
| Secondary | Change from Baseline in Tumor Necrosis Factor-alpha (TNF-α) | Baseline and Week 12 | Evaluated as the absolute change in plasma TNF-α levels | ClinicalTrials.gov |
| Secondary | Change from Baseline in Interleukin-6 (IL-6) | Baseline and Week 12 | Evaluated as the absolute change in plasma IL-6 levels | ClinicalTrials.gov |
| Secondary | Change from Baseline in Alanine Transaminase (ALT) | Baseline and Week 12 | Evaluated as the absolute change in serum ALT levels | ClinicalTrials.gov |
| Secondary | Change from Baseline in Alkaline Phosphatase (ALP) | Baseline and Week 12 | Evaluated as the absolute change in serum ALP levels | ClinicalTrials.gov |
| Secondary | Change from Baseline in Body Weight | Baseline and Week 12 | Evaluated as the absolute change in body weight in kilograms | ClinicalTrials.gov |
| Secondary | Change from Baseline in Body Mass Index (BMI) | Baseline and Week 12 | Evaluated as the absolute change in BMI (calculated as weight in kilograms divided by height in meters squared) | ClinicalTrials.gov |
| Secondary | Change from Baseline in Systolic Blood Pressure (SBP) | Baseline and Week 12 | Evaluated as the absolute change in resting systolic blood pressure | ClinicalTrials.gov |
| Secondary | Change from Baseline in Diastolic Blood Pressure (DBP) | Baseline and Week 12 | Evaluated as the absolute change in resting diastolic blood pressure | ClinicalTrials.gov |
| Secondary | Change from Baseline in Waist Circumference (WC) | Baseline and Week 12 | Evaluated as the absolute change in waist circumference | ClinicalTrials.gov |
| Secondary | Change from Baseline in Hip Circumference (HC) | Baseline and Week 12 | Evaluated as the absolute change in hip circumference | ClinicalTrials.gov |
| Secondary | Change from Baseline in Thigh Circumference (TC) | Baseline and Week 12 | Evaluated as the absolute change in thigh circumference | ClinicalTrials.gov |
| Secondary | Change from Baseline in Body Fat Percentage | Baseline and Week 12 | Evaluated as the absolute change in body fat percentage | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)